Literature DB >> 23069689

Lymph node fine needle cytology in the diagnosis of infectious diseases and ancillary techniques.

L V Sosa Fernandez1, F Plaitano, V Varone, I Cozzolino.   

Abstract

Fine needle cytology (FNC) is represents a valid tool in the diagnosis of lymphadenopathies. When rapid on site evaluation (ROSE) is performed the method overcomes the problems related to the adequacy and allows to store residual material for ancillary techniques future. Cytological data, obtained by FNC may be supported and integrated by ancillary techniques namely molecular biology. The detection of specific microorganisms based on nucleic-acid technologies is the fundamental principle of molecular techniques, allowing a rapid diagnosis, an immediate treatment with minimal invasion and costs for the patient. Molecular procedures are also characterized by high levels of specificity and sensitivity. In conclusion, morphological diagnosis of infectious diseases performed on FNC samples can be enhanced by molecular analysis data.

Entities:  

Mesh:

Year:  2012        PMID: 23069689

Source DB:  PubMed          Journal:  Infez Med        ISSN: 1124-9390


  3 in total

1.  Application of microbiological rapid on-site evaluation in respiratory intensive care units: a retrospective study.

Authors:  Yi Tao; Licheng Song; Han Fu; Wei Zhang; Yuwei Song; Hongxiang Liu; Lixin Xie; Kaifei Wang
Journal:  Ann Transl Med       Date:  2022-01

Review 2.  Nodular goiter with amyloid deposition in an elderly patient: fine-needle cytology diagnosis and review of the literature.

Authors:  Vincenzo Di Crescenzo; Alfredo Garzi; Fara Petruzziello; Mariapia Cinelli; Lucio Catalano; Pio Zeppa; Mario Vitale
Journal:  BMC Surg       Date:  2013-10-08       Impact factor: 2.102

Review 3.  Early cytological diagnosis of extranodal stage I, primary thyroid Non-Hodgkin lymphoma in elderly patients. Report of two cases and review of the literature.

Authors:  Elena Vigliar; Alessia Caleo; Mario Vitale; Vincenzo Di Crescenzo; Alfredo Garzi; Pio Zeppa
Journal:  BMC Surg       Date:  2013-10-08       Impact factor: 2.102

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.